Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 08 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 5 pages · English

Summary by 6ix AI

The agreement allows Zydus's subsidiary, Sentynl Therapeutics, to acquire global rights to NULIBRY and manage its development and commercialization. This acquisition aims to address unmet healthcare needs for children with molybdenum cofactor deficiency, a life-threatening condition. The press release emphasizes Zydus's commitment to empowering patients with rare diseases through innovative therapies.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Cadila Healthcare Limited has informed the Exchange about press release dated 08-Mar-2022 titled Sentynl Therapeutics Inc., a wholly owned subsidiary of Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) and BridgeBio Pharma Announce Asset Purchase Agreement for BridgeBio Pharma���s

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases